ArticleGenes & development2004
Attenuation of estrogen receptor alpha-mediated transcription through estrogen-stimulated recruitment of a negative elongation factor.
Article in Genes & development, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 110 citations in OpenAlex.
- RNA polymerase II pausing in development: orchestrating transcription.Open biology · 2022Review
- Role of NELF-B in supporting epithelial-mesenchymal transition and cell proliferation during hepatocellular carcinoma progression.Oncology letters · 2021Article
- CDK9 keeps RNA polymerase II on track.Cellular and molecular life sciences : CMLS · 2021Review
- Topoisomerase IIα represses transcription by enforcing promoter-proximal pausing.Cell reports · 2021Article
- Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression.Journal of experimental & clinical cancer research : CR · 2021Article
- The negative elongation factor NELF promotes induced transcriptional response of Drosophila ecdysone-dependent genes.Scientific reports · 2021Article
- Estrogen receptor alpha (ERα)-mediated coregulator binding and gene expression discriminates the toxic ERα agonist diethylstilbestrol (DES) from the endogenous ERα agonist 17β-estradiol (E2).Cell biology and toxicology · 2020Article
- NELF Regulates a Promoter-Proximal Step Distinct from RNA Pol II Pause-Release.Molecular cell · 2020Article
- How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?DNA repair · 2019Review
- Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.Scientific reports · 2018Article
- Article
- Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis.Nature communications · 2017Article
- Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer.Oncotarget · 2016Article
- Article
- Genetic suppression reveals DNA repair-independent antagonism between BRCA1 and COBRA1 in mammary gland development.Nature communications · 2016Article
- RNA polymerase II pausing as a context-dependent reader of the genome.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2016Review
- Kinetically Defined Mechanisms and Positions of Action of Two New Modulators of Glucocorticoid Receptor-regulated Gene Induction.The Journal of biological chemistry · 2016Article
- Ready, pause, go: regulation of RNA polymerase II pausing and release by cellular signaling pathways.Trends in biochemical sciences · 2015Review
- Translational Initiation at a Non-AUG Start Codon for Human and Mouse Negative Elongation Factor-B.PloS one · 2015Article
- A phosphotyrosine switch determines the antitumor activity of ERβ.The Journal of clinical investigation · 2014Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
Estrogen receptor alpha (ERalpha) signaling is paramount for normal mammary gland development and function and the repression of breast cancer. ERalpha function in gene regulation is mediated by a number of coactivators and corepressors, most of which are known to modify chromatin structure and/or influence the assembly of the regulatory complexes at the level of transcription initiation. Here we describe a novel mechanism of attenuating the ERalpha activity. We show that cofactor of BRCA1 (COBRA1), an integral subunit of the human negative elongation factor (NELF), directly binds to ERalpha and represses ERalpha-mediated transcription. Reduction of the endogenous NELF proteins in breast cancer cells using small interfering RNA results in elevated ERalpha-mediated transcription and enhanced cell proliferation. Chromatin immunoprecipitation reveals that recruitment of COBRA1 and the other NELF subunits to endogenous ERalpha-responsive promoters is greatly stimulated upon estrogen treatment. Interestingly, COBRA1 does not affect the estrogen-dependent assembly of transcription regulatory complexes at the ERalpha-regulated promoters. Rather, it causes RNA polymerase II (RNAPII) to pause at the promoter-proximal region, which is consistent with its in vitro biochemical activity. Therefore, our in vivo work defines the first corepressor of nuclear receptors that modulates ERalpha-dependent gene expression by stalling RNAPII. We suggest that this new level of regulation may be important to control the duration and magnitude of a rapid and reversible hormonal response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.